Is elotuzumab chemotherapy?
Drug Type: Elotuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as a “monoclonal antibody (anti SLAMF7)”.
What does Elotuzumab target?
Elotuzumab is a humanized IgG1 kappa immunostimulatory monoclonal antibody targeting and binding the extracellular domain of SLAMF7, without interacting with other members of the SLAM family. Elotuzumab binds SLAMF7 expressed both on MM and NK cells, but affects these cells differently.
Is elotuzumab FDA approved?
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who …
How long is elotuzumab infusion?
Briefly, during Cycle 1, the elotuzumab infusion rate was increased, in the absence of IRs at each step, from 0.5 to 2 mL/min during dose 1 (dura- tion 2 h 50 min), from 3 to 4 mL/min during dose 2 (duration 1 h 13 min), and to 5 mL/min for all subsequent doses (duration <1 h).
Is elotuzumab an immunotherapy?
Immunotherapy with monoclonal antibodies, such as elotuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
What type of drug is elotuzumab?
Elotuzumab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells.
What is the cost of elotuzumab?
The cost for Empliciti intravenous powder for injection 300 mg is around $2,098 for a supply of 1 powder for injection, depending on the pharmacy you visit.
When was elotuzumab approved by the FDA?
The FDA approved elotuzumab in November 2015 for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received 1 to 3 prior therapies.
Is Isatuximab FDA approved?
On March 31, 2021, the FDA approved isatuximab-irfc (brand name Sarclisa) in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Is elotuzumab chemotherapy or immunotherapy?
EMPLICITI fights multiple EMPLICITI is an immunotherapy medicine that works with your immune system to fight multiple myeloma. EMPLICITI works in the following ways: It activates a key type of white blood cell in your immune system, called a natural killer (NK) cell.
Who makes Empliciti?
Bristol Myers Squibb and AbbVie are co-developing Empliciti, with Bristol Myers Squibb solely responsible for commercial activities.
What is elotuzumab used for?
Elotuzumab injection is used together with lenalidomide and dexamethasone to treat multiple myeloma (a blood cell cancer) in patients who have received one to three previous cancer treatments.